JNJ met main goal in late-stage trial for ulcerative colitis treatment

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with moderately to severely active ulcerative colitis met both its primary and secondary goals.

The study demonstrated statistically significant and clinically